T1	Participants 276 325	childhood acute lymphoblastic leukaemia (UKALL X)
T2	Participants 337 522	patients aged 0-14 years inclusive with an initial white blood count of less than 100 x 10(9)/l to receive an early intensification block, a late intensification block, both, or neither
T3	Participants 220 265	Medical Research Council (MRC) United Kingdom
T4	Participants 689 789	all patients were also randomised between late intensification alone and both early plus late blocks
T5	Participants 554 656	children aged 1-14 years, randomised between different central nervous system (CNS) directed therapies
